Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oxaliplatin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    695 result(s) found for: Oxaliplatin. Displaying page 1 of 35.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-002202-37 Sponsor Protocol Number: 2015-115 Start Date*: 2016-01-06
    Sponsor Name:radboudumc
    Full Title: Pilot study: Is concomitant administration of lidocaine during oxaliplatin infusion able to prevent pain as a result of oxaliplatin induced acute neuropathy?
    Medical condition: Acute oxaliplatin induced neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001018-76 Sponsor Protocol Number: CA209-649 Start Date*: 2016-10-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Ga...
    Medical condition: Gastric or Gastroesophageal Junction Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Completed) PL (Completed) HU (Completed) DE (Completed) PT (Completed) FR (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005088-25 Sponsor Protocol Number: 01234 Start Date*: 2006-11-15
    Sponsor Name:Leiden University Medical Center
    Full Title: Phase I/II study of oxaliplatin combined with melphalan in isolated hepatic perfusion for the treatment of liver metastases.
    Medical condition: Patients with isolated hepatic metastases of histologically confirmed colorectal adenocarcinoma and for the phase I study also isolated hepatic metastases of all other solid tumors.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002576-27 Sponsor Protocol Number: ICM-URC2016/27 Start Date*: 2017-03-01
    Sponsor Name:Institut régional du Cancer de Montpellier
    Full Title: Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter ...
    Medical condition: colon cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009955 Colon cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001097-24 Sponsor Protocol Number: OE7-432-LOR-0033-I Start Date*: 2007-07-19
    Sponsor Name:Technische Universitaet Muenchen, Medizinische Fakultaet
    Full Title: Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.
    Medical condition: Locally advanced oesophageal squamous cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003187-32 Sponsor Protocol Number: etoxel-01-2005 Start Date*: 2005-12-19
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: A phase II study of etoposide, oxaliplatin and capecitabine in patients with advanced hepatocellular carcinoma
    Medical condition: Advanced Hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001959-38 Sponsor Protocol Number: 2005-001959-38 Start Date*: 2005-07-07
    Sponsor Name:Gedske Daugaard
    Full Title: Fase II trial with gemcitabine and oxaliplatin in patients with unknown primary tumours
    Medical condition: To test the effect of Gemcitabine and axaliplatin in patients with unknown primary tumours and performance 2 or age 66 to 75
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005289-11 Sponsor Protocol Number: oxaliplatine 1 Start Date*: 2008-10-08
    Sponsor Name:Institut Jules Bordet
    Full Title: A non randomized , stratified phase II trial evaluating efficacy and safety of oxaliplatin in combination with 5-Fluorouracil in patients with platinum-sensitive and platinum-resistant recurrent ov...
    Medical condition: ovarian carcinoma in relapse
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005169-36 Sponsor Protocol Number: NKV110721 Start Date*: 2008-02-07
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: NKV110721, A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin-Induced Nausea and Vomiting
    Medical condition: Prevention of nausea and vomiting due to first cycle of oxaliplatin based chemotherapy in patients with colorectal cancer receiving a combination with 5-fluorouracil and leucovorin, or in combinati...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) HU (Completed) IT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001333-88 Sponsor Protocol Number: ACTION Start Date*: 2014-10-16
    Sponsor Name:Academic Medical Center
    Full Title: A phase Ib/II study on the addition of Nab-paclitaxel (Abraxane) to capecitabine and oxaliplatin in the first-line treatment of metastastasized oesophagogastric carcinoma
    Medical condition: Metastasized oesophagogastric carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012040-16 Sponsor Protocol Number: EMR62242–004 Start Date*: 2009-10-06
    Sponsor Name:Merck KGaA
    Full Title: An open-label, randomized, controlled, multi-center, Phase I/II trial investigating 2 EMD 525797 doses in combination with cetuximab + irinotecan versus cetuximab + irinotecan alone, as second-line...
    Medical condition: Subjects with k-ras WT, metastatic colorectal cancer who have failed a fist line chemotherapy with an oxaliplatin-containing regimen will be eligible for this trial.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) CZ (Completed) GB (Completed) HU (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005675-34 Sponsor Protocol Number: CS1008-A-E203 Start Date*: 2009-07-01
    Sponsor Name:Daiichi Sankyo Development Ltd
    Full Title: A PHASE 2 OPEN-LABEL RANDOMISED, TRIAL OF CS-1008 IN COMBINATION WITH IRINOTECAN VS IRINOTECAN ALONE IN SUBJECTS WITH METASTATIC COLORECTAL CARCINOMA WHO FAILED FIRST LINE OXALIPLATIN BASED CHEMOTH...
    Medical condition: Second-line therapy for previously-treated advanced or metastatic colorectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052360 Colorectal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012151-23 Sponsor Protocol Number: SPON 671-09 Start Date*: 2009-11-11
    Sponsor Name:Cardiff University
    Full Title: A randomised phase II study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer ...
    Medical condition: Metastatic Colorectal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000048-89 Sponsor Protocol Number: AFLIBL06266 Start Date*: 2012-05-23
    Sponsor Name:sanofi-aventis France
    Full Title: A Multicenter, Single arm, Open Label Clinical Trial Evaluating Safety and Health-Related Quality of Life of Aflibercept in Combination with Irinotecan/5FU chemotherapy (FOLFIRI) in Patients with ...
    Medical condition: Colorectal Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-003898-86 Sponsor Protocol Number: HL BOR 001 Start Date*: 2005-03-07
    Sponsor Name:Institut jules Bordet
    Full Title: EVALUATION OF THE TREATMENT OF PERITONEAL CARCINOMATOSIS OF COLORECTAL ORIGIN THROUGH COMPLETE RESECTION AND HYPERTHERMIC INTRA-PERITONEAL PEROPERATIVE CHEMOTHERAPY (HIPEC) WITH OXALIPLATIN
    Medical condition: Peritoneal carcinomatosis secondary to a carcinoma of colorectal or appendicular origin
    Disease: Version SOC Term Classification Code Term Level
    7.0 10039867 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000945-36 Sponsor Protocol Number: XALIP_C_02090 Start Date*: 2007-09-18
    Sponsor Name:sanofi-aventis groupe
    Full Title: A multicenter, randomized, double blind, placebo controlled Phase III study to assess the efficacy of xaliproden in patients with oxaliplatin-induced peripheral sensory neuropathy (PSN) following a...
    Medical condition: Patient with oxaliplatin-induced peripheral sensory neuropathy after having completed an oxaliplatin-containing chemotherapy regimen post complete surgical removal of primary colorectal tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040039 Sensory peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000192-17 Sponsor Protocol Number: GO-80, V1 18 Mar 05 Start Date*: 2005-05-18
    Sponsor Name:Barts & The London NHS Trust
    Full Title: Gemcitabine and Oxaliplatin in the treatment of locally advanced or metastatic transitional cell carcinoma of the urinary tract in patients with impaired renal function and patients who have progr...
    Medical condition: Locally advanced or metastatic transitional cell carcinoma of the urinary tract
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001834-34 Sponsor Protocol Number: 4919 Start Date*: 2006-03-14
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: Phase 2 trial of neo-adjuvant Oxaliplatin and 5-fluorouracil in oesophageal cancer
    Medical condition: Operable oesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005666-12 Sponsor Protocol Number: IMA910-101 Start Date*: 2008-04-15
    Sponsor Name:immatics biotechnologies GmbH
    Full Title: An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyc...
    Medical condition: Adult HLA-A*02-positive patients who have been diagnosed with unresectable, locally advanced and/or metastatic colorectal cancer before first-line chemotherapy. Patients must have completed a 12 we...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) GB (Completed) LV (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000820-42 Sponsor Protocol Number: EFC10262 Start Date*: 2008-06-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan...
    Medical condition: Patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5FU combination (FOLFIRI) after failure of an oxaliplatin based regimen.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GR (Completed) NL (Completed) CZ (Completed) EE (Completed) ES (Completed) DK (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 13:01:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA